NJEDA Closes on 2 New NJ Innovation Evergreen Fund Investments

On Aug 1, 2025

The New Jersey Economic Development Authority (NJEDA) recently closed on two new investments through the New Jersey Innovation Evergreen Fund (NJIEF). Nascent Materials, Inc. received an initial Qualified Investment of $750,000 through an application for co-investment submitted by the Princeton-based venture capital firm, SOSV. Additionally, Enquyst Technologies, Inc. received an initial Qualified Investment of $3 million through an application for co-investment submitted by the New York City-based venture capital firm Eckuity Capital.

The NJIEF, launched in 2022, is a unique tool to increase access to strategic resources and venture capital in New Jersey. Under the NJIEF, the State acts as an equity investor in early-stage companies, deploying up to $600 million into companies alongside professional venture capital firms. The Evergreen Fund currently has approximately $19 million of unallocated capital available to fund additional investments into high-growth businesses in New Jersey.

“The NJEDA’s funding for Nascent Materials and Enquyst will accelerate each companies’ growth by providing essential resources for success. With four investments already made, the New Jersey Innovation Evergreen Fund shows no signs of slowing, demonstrating the state’s strong commitment to supporting young, innovative ventures,” said Kathleen Coviello, chief economic transformation officer of the NJEDA. “NJIEF’s continuous venture capital investments in high-growth startups play a key role in driving job creation and economic growth across the state.”

Nascent Materials develops cost-effective cathode active materials, a key input in lithium-ion batteries. Cathodes are the single most expensive component of lithium-ion batteries, representing roughly 40% of total battery cell cost, with current cathode production capacity largely stemming from manufactures based in China. Nascent Materials is currently working out of SOSV-sponsored HAX, a startup development program and Strategic Innovation Center for pre-seed hard tech companies located in Newark. NJEDA’s investment of $750,000 into Nascent Materials’ Seed fundraising round attracted additional international and out-of-state capital of $1,550,000 resulting in /private/ public multiplier of 2:1.

“While the U.S. has both the lithium resources and strong end-market demand for batteries, we continue to lag in one of the most strategic segments of the value chain: cathode manufacturing. This bottleneck has left domestic cell manufacturers overly reliant on foreign suppliers for their most expensive and technically complex input,” said Chaitanya Sharma, Founder and CEO of Nascent Materials. “This investment from NJEDA enables us to expand our operations in New Jersey and build the foundation for a resilient, homegrown supply chain. With its exceptional engineering talent, global port access, and critical position in national logistics networks, New Jersey is uniquely positioned to become a key hub in the emerging U.S. battery belt. We’re proud to be part of that vision and excited to grow alongside a state that’s actively investing in clean energy innovation and advanced manufacturing.”

Founded in 2017 and headquartered in Short Hills, Enquyst Technologies is a manufacturing technology company that developed an advanced modular equipment and process platform designed to enhance biomanufacturing, specifically in the purification of complex drugs. The company’s platform focuses on the production of monoclonal antibodies (mAbs), bispecific antibodies, protein therapeutics, biosimilars, and gene therapies, all of which are high-demand market segments in biologics, with mAbs being the largest.

Currently, the production capacity for these drugs meets only 50 percent of the market’s demand, with Enquyst looking to close that gap. Enquyst was founded in Boston, Massachusetts where the technology has been developed, but is pivoting its core operations to New Jersey as a result of the proposed Program investment and to leverage the State’s strong biotech ecosystem. NJEDA’s investment into Enquyst is expected to catalyze additional private funding on a 3:1 basis.

“For decades, we have seen minimal innovation in bioprocessing, due to the highly regulated and conservative nature of the biotech and biopharma industries. Strategies fall short in meeting the cost and purification demands of today’s increasingly diverse biological medicines,” said Dr. Jason Criscione, founder and CSO of Enquyst Technologies. “Our platform technology is disrupting biological drug manufacturing by enabling truly continuous processing, delivering best-in-class purity with no yield loss, offering flexibility across diverse biological drug classes, and lowering downstream processing costs by more than 70 percent. With investment from NJEDA and Eckuity Capital, Enquyst is expanding its NJ footprint to facilitate early adoption through strategic partnerships within the region’s biomanufacturing ecosystem.”

Eckuity Capital was established in 2021 and is based in New York City. The firm invests in companies with innovative solutions that it judges can achieve commercialization faster than traditional timelines, with a focus on life sciences, devices and diagnostics, and digital health. Enquyst Technologies represents Eckuity’s first investment in a New Jersey-based business.

To access more business news, visit NJB News Now.

Related Articles: